Histologic subtypes of urothelial carcinoma: an update

The role of intravesical treatment, neoadjuvant or adjuvant chemotherapy has not been well characterized for most subtypes, and prospective data are inadequate. Understanding detailed molecular biology of these tumors, development of personalized biomarkers and design of clinical trials focusing specifically on S/DDs with worse prognosis are needed to improve patient care.